Kaneka Nutrients announces The International Coenzyme Q10 Association Ninth Scientific Meeting

Food and Healthcare Press Releases Tuesday November 14, 2017 09:07
PASADENA, Texas--14 Nov--PRNewswire/InfoQuest
June 21-24, 2018 at Columbia University, NYC

The International Coenzyme Q10 Association (ICQA; http://icqaproject.org/ ) is a non-profit organization that fosters basic and applied biomedical research on Coenzyme Q10 (CoQ10). Their mission is to advance knowledge on basic biochemistry and molecular genetics, as well as preventive and therapeutic effects of CoQ10.   Kaneka Nutrients ( www.kanekanutrients.com ) is a founding member and proud to partner with ICQA for the Ninth Scientific Meeting to be held in at Columbia University in New York City June 21 – 24, 2018.

"We have not held our Scientific Meeting in the United States in over 10 years.   As such, we are excited to bring this meeting back to the United States.   Previous Scientific Meetings have been held in Japan and Europe," said Dr. Placido Navas, Chairman of The International Coenzyme Q10 Association.

Every two to three years, nearly 350+ researchers and other professionals choose to attend the ICQA International Scientific Meeting to learn about the latest advances of Conventional CoQ10 and the Ubiquinol form of CoQ10, meet with colleagues from around the world and strike new collaborations.

The critical goals of the ICQA are to promote international collaborative research efforts to expand scientific knowledge and to optimize the use of CoQ10 as preventative and therapeutic interventions in human health. To achieve these important goals, ICQA organizes an international scientific meeting to present cutting-edge CoQ10 and Ubiquinol CoQ10 research in major clinical topics including: mitochondrial and degenerative diseases, aging, cardiovascular disorders, and nutritional supplementation needs and mechanisms that can benefit people suffering these conditions.

Dr. Navas added, "As in the 2015 Bologna Scientific Meeting, exciting sessions on the areas of CoQ10 and Ubiquinol CoQ10 research that have advanced significantly in the last few years will be presented including: mitochondrial diseases (primarily CoQ10 deficiency syndrome), cardiovascular diseases, diabetes, and aging. There is evidence of efficacy of CoQ10 supplementation in these conditions. Significantly, the European Medicines Agency has recently registered Ubiquinol as an orphan drug for CoQ10 deficiency syndrome."

Mark your calendars for this important Scientific Meeting to learn about the advances of Conventional CoQ10 and the Ubiquinol form of CoQ10.   Visit icqaproject.org for more information and to register.
Contact Information:
Ron Martin
Kaneka Nutrients
+1-281-291-3185

Latest Press Release

Merck Awarded Australian CRISPR Nickase Patent for Foundational Genome-Editing Technology

- Patent covers paired Cas9 nickase technology to reduce off-target effects, advance gene therapy and research - Expands company's foundational CRISPR cutting and integration IP necessary to correct genetic defects in gene therapy patients - Merck to...

Kaneka officially starts continuous manufacturing under GMP

Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Mamoru Kadokura) have installed continuous manufacturing equipment to be applied to pharmaceutical products at Kaneka Singapore Co. (Pte.) Ltd, (Headquarters: Singapore; President: Kazuhiko...

TIENS Group opens new high-tech Experience Store in Shenzhen

TIENS Group, one of leading corporations in the Healthcare industry, unveiled a new high-tech Customer Experience Store in Shenzhen. Li Jinyuan, founder and chairman of TIENS group, announced the official opening of its first store in the world on August...

Sotera Health#s Nordion completes the sale of its medical isotopes business to BWXT

- Nordion's increased focus on gamma technologies supports Sotera Health's company-wide commitment to Safeguarding Global Health(TM) Sotera Health LLC, the world's leading, fully integrated protector of global health, today announced the closing of the...

Menarini Ricerche to Sponsor Cancer Trial in Acute Myeloid Leukemia in USA

Menarini Ricerche, a company of the Menarini Group, announced today that the sponsorship of the ongoing Phase I/II study that is investigating MEN1703/SEL24 for the treatment of patients with relapsed/refractory (R/R) AML in the USA has been transferred...

Related Topics